Atlas Trials

Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer

Clinical trial NCT03253068 · UNKNOWN

Trial details

NCT number
NCT03253068
Sponsor
Wakayama Medical University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Small Cell Lung Cancer Extensive Stage
Start date
2017-08-01
Primary completion
2020-12-28
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.